The Oncology Institute Stock Current Valuation
| TOIIW Stock | USD 0.01 0.00 0.00% |
Valuation analysis of The Oncology Institute helps investors to measure Oncology Institute's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to climb to -3.19 in 2024. Enterprise Value Multiple is likely to climb to -3.19 in 2024.
Fairly Valued
Today
Please note that Oncology Institute's price fluctuation is out of control at this time. Calculation of the real value of The Oncology Institute is based on 3 months time horizon. Increasing Oncology Institute's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Oncology stock is determined by what a typical buyer is willing to pay for full or partial control of The Oncology Institute. Since Oncology Institute is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oncology Stock. However, Oncology Institute's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0125 | Real 0.0124 | Hype 0.01 | Naive 0.0139 |
The intrinsic value of Oncology Institute's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oncology Institute's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of The Oncology Institute helps investors to forecast how Oncology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncology Institute more accurately as focusing exclusively on Oncology Institute's fundamentals will not take into account other important factors: The Oncology Institute Company Current Valuation Analysis
Oncology Institute's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Oncology Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncology Institute is extremely important. It helps to project a fair market value of Oncology Stock properly, considering its historical fundamentals such as Current Valuation. Since Oncology Institute's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncology Institute's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncology Institute's interrelated accounts and indicators.
Click cells to compare fundamentals
Oncology Current Valuation Historical Pattern
Today, most investors in Oncology Institute Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oncology Institute's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Oncology Institute current valuation as a starting point in their analysis.
Oncology Institute Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, The Oncology Institute has a Current Valuation of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and about the same as Health Care (which currently averages 0.0) industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
The Oncology Institute is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 184.34 Million. Oncology Institute adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.Oncology Fundamentals
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Number Of Shares Shorted | 2.64 K | ||||
| Revenue | 324.24 M | ||||
| EBITDA | (70.45 M) | ||||
| Net Income | (83.07 M) | ||||
| Cash And Equivalents | 15.17 M | ||||
| Total Debt | 119.67 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 1.76 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (36.31 M) | ||||
| Earnings Per Share | (602.09) X | ||||
| Number Of Employees | 800 | ||||
| Beta | 0.62 | ||||
| Total Asset | 209.24 M | ||||
| Retained Earnings | (146.15 M) | ||||
| Working Capital | 108.7 M | ||||
| Net Asset | 209.24 M |
About Oncology Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze The Oncology Institute's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncology Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of The Oncology Institute based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.